Navigation Links
New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
Date:4/17/2008

Berlin, Germany: A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumour regression in breast cancer after only six weeks of use, a scientist told the 6th European Breast Cancer Conference (EBCC-6) today (Thursday 17 April). Dr. Angel Rodriguez, from the Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, USA, said that the work demonstrated for the first time that the tyrosine kinase inhibitor lapatinib could decrease tumour-causing breast cancer stem cells in the primary breast cancers of women receiving neoadjuvant treatment (treatment given before the primary surgery for the disease).

Dr. Rodriguez and colleagues studied 45 patients with locally advanced breast cancer in which the gene HER-2 was over-expressed. The patients received lapatinib for six weeks, followed by a combination of weekly trastuzumab and three-weekly docetaxel, given over 12 weeks, before primary surgery. Biopsies were performed at the time of diagnosis and also after six weeks of lapatinib and cells from the tumours were obtained and analyzed.

We saw significant tumour regression after six weeks of single agent lapatinib, said Dr. Rodriguez. Bi-dimensional tumour measurements showed a median decrease of minus 60.8%. We had previously showed that tumour-causing breast cancer stem cells were resistant to conventional preoperative chemotherapy; indeed, residual cancers that were exposed to such chemotherapy showed an increase in tumour-causing cells and enhanced tumour initiation by the formation of mammospheres, small tumours that form when tumour-causing cells are cultured in a test tube, which reflect the capacity of the cells to self-renew. So we were excited to see that the results with lapatinib were different.

Dr. Rodriguezs results suggest that specific signalling inhibitors of the pathways responsible for stem cell self-renewal could provide a poss
'/>"/>

Contact: Mary Rice
mary@mrcommunication.org
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2

Related biology news :

1. Single-largest biodiversity survey says primary rainforest is irreplaceable
2. UNH becomes first university in nation to use landfill gas as primary energy source
3. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
4. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
5. Pregnant patients lose out in breast cancer treatment; a new approach is needed
6. Improving care and knowledge in translational research to fight breast cancer
7. Evidence now suggests eating soy foods in puberty protects against breast cancer
8. T-cadherin affects blood vessel growth in breast cancer, hormone from fat cells may play a role
9. MU researcher links hormone replacement therapy to breast cancer
10. Gene variant increases breast cancer risk
11. High levels of estrogen associated with breast cancer recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... SPRINGS, Florida , July 8, 2015 ... constantly evolving as this summer,s must have products such as ... in demand as popularity for biometrics based devices continues to ... are NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: ... Inc. (NYSE: FIT ), GoPro, Inc. (NASDAQ: GPRO ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
(Date:7/2/2015)... GOTHENBURG, Sweden , July 2, 2015 ... fingerprint sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor ... is one of FPC,s distributors in Asia ... Q4 2015. The sensors will be used by smartphone manufacturers ... 268 MSEK is included in the communicated revenue guidance of ...
Breaking Biology News(10 mins):Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... , This release is available in French ... health. However, some people have inherited conditions that leave them ... prone to serious health problems, including developmental delay, psychosis, stroke ... genetic disease related to vitamin B12 deficiency by identifying a ...
... native vegetation offer birds "mini-refuges" and help to offset ... a study published today in the journal PLOS ... those with traditional grass lawns and non-native plantings. ... (NSF) Central Arizona-Phoenix Long-Term Ecological Research (LTER) site, one ...
... many reasons why it is important to be able to ... identification marks are essential for ensuring the correctness of breeding ... the possibility of deceit in competitions or when animals are ... relies on branding with hot irons or on ear-tagging but ...
Cached Biology News:Vitamin B12 deficiency: Tracking the genetic causes 2Native plants in urban yards offer birds 'mini-refuges' 2Native plants in urban yards offer birds 'mini-refuges' 3The end of an era? Branding horses does not enable them to be identified 2
(Date:7/29/2015)... -- AmnioChor Inc., an early stage biotech startup based on ... that the Musculoskeletal Transplant Foundation of Edison ... seed round of development of the proprietary AmnioCept™ product ... AmnioChor,s technology allows cryopreservation of the amniotic membrane ... within those tissues. Amnion is a well-established source of ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE MKT: ... results will be released on Thursday, August 13, 2015, ... Time, Pfenex management will host a conference call to ... A press release outlining the financial results and business ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) ...
(Date:7/29/2015)... ... 29, 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers ... drug/device combinations. The current system received a score of 0 (range -10 to +10) ... (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... 9:00 a.m. Eastern Time on March 16, 2009 ... (Nasdaq: UTHR ) announced today that, based ... and Drug Administration (FDA), the FDA,s pending regulatory review ... treprostinil) will likely extend beyond its originally anticipated April ...
... Pangu BioPharma to SpeakSAN DIEGO, March 16 aTyr ... and development of an entirely new class of natural ... that it will participate at the ChinaBio(R) Investor Forum ... Cai, Senior Vice President of Clinical Development a aTyr ...
... cutting net operating expenses by approximately 50% in 2009 CTI ... March 16 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... fourth quarter and year ended December 31, 2008. Recent Events ... Met primary endpoint in the Phase ...
Cached Biology Technology:United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso) 2United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso) 3aTyr Pharma to Present at ChinaBio(R) Investor Forum in Hong Kong 2Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 2Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 3Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 4Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 5Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 6Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 7Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 8
...
... Mouse Monoclonal to L1 Cell Adhesion ... which is located in Xq28, is involved ... of the aqueduct of Sylvius); 2) MASA ... and 3) SPG1 (spastic paraplegia). ...
...
... One-Step FP Standardization Kit is used ... fluorescence polarization values of fluorescein solutions ... 2000 System. It also allows users ... by their instrument to the expected ...
Biology Products: